Is BCH worth the price difference against GL Biochem (Shanghai) on measured results?

What I am working with: BCH · GL Biochem (Shanghai).

I suspect the honest answer is that it depends, in which case I would like to know on what.

Assume I can obtain either option without difficulty, so availability is not the deciding factor.

Under what conditions does the answer flip?

Start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

On declarations: the accurate description of a research reference material is a research reference material, and accuracy is both the legal position and the practical one. A declaration that misdescribes the contents converts a customs question into a different kind of question, and it does so on a document with your name on it.

The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.

I would resist treating a long track record as evidence of current quality. Suppliers change synthesis partners, fill sites and staff, and a 2024 result is weak evidence about a 2026 lot.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.

edited 2 Jul 2026 by loss_on_drying — removed a claim I could not source

A lane is a physical object with a temperature profile and a customs regime, and choosing one is a real decision rather than a shipping-option checkbox.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

The underlying point is that the diagnostic red flags, in rough order of how much they tell you: a certificate whose lot number does not match the vial; a certificate with no method section; a purity figure quoted to two decimal places with no chromatogram; a testing date that precedes the stated manufacturing date; identical certificates across nominally different lots; and "sterile filtered" offered in place of a sterility test. Each of those is a specific inference, not a vibe.

The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

Worth being precise here: evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

Personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

Regulatory positions on personal importation are published: the relevant frameworks are the US FDA’s personal importation policy in its Regulatory Procedures Manual, the UK MHRA’s guidance on importing medicines for personal use, and the equivalent national provisions in the EU member states and Australia’s Therapeutic Goods Administration personal importation scheme. They differ materially from each other.

Test the first lot from any new supplier, set your accept threshold before the result arrives, and keep the certificate with the lot number and the date in one place.

The part that matters: the structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.

The consumer-protection question about a stablecoin transfer has a simple answer: you give up reversibility entirely. There is no chargeback, no acquirer, no dispute process. What you retain is the on-chain record, which proves that a transfer happened and to which address — useful for establishing that you paid, useless for getting the money back. That asymmetry is the whole risk profile.

Independent testing costs have been stable enough over the past two years that amortisation arithmetic across a lot is worth doing before choosing a lot size, and the numbers usually favour a larger lot tested once over several small lots tested never.

If a supplier will not send you a lot-specific certificate before you order, you have learned something useful at zero cost.